Announcement on the Wholly-Owned Subsidiary Receiving the CEP Certificate for Everolimus API
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
Announcement on the Wholly-Owned Subsidiary Receiving the CEP Certificate for Everolimus API
Filed with SSE · · 2 pages · Chinese and English
Release
Zhejiang Hisun Pharmaceutical Co., Ltd. on 6ix
Earlier from Zhejiang Hisun Pharmaceutical
- Announcement on Progress in Public Transfer of 100% Equity in the Wholly-owned Subsidiary Zhejiang Pharmaceutical Industry Corp., Ltd.
- Announcement on Wholly-owned Subsidiary's Passing GMP Compliance Inspection for Drugs
- Announcement on Resolutions of the 9th Meeting of the 10th Board of Directors
- Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2025
- Announcement on Public Transfer of 100% Equity in the Wholly-owned Subsidiary Zhejiang Pharmaceutical Industry Corp., Ltd.
Later from Zhejiang Hisun Pharmaceutical
- Notice on Convening the 1st Extraordinary General Meeting in 2026
- Announcement on the Subsidiary Obtaining New Veterinary Drug Registration Certificate
- Announcement on HS387 Tablets Obtaining the U.S. FDA Approval for Clinical Trials of a New Drug
- Announcement on Obtaining the Notice on Approval of Drug Supplement Application
- Indicative Announcement on Convening the 1st Extraordinary General Meeting in 2026
Follow Zhejiang Hisun Pharmaceutical into a list and get an email when it puts out news.
Follow Zhejiang Hisun Pharmaceutical